Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management

Shah, Shailja C.; Itzkowitz, Steven H.

doi:10.1053/j.gastro.2021.10.035

Cited by 372 publications

(251 citation statements)

References 132 publications

Supporting

Mentioning

230

Contrasting

Unclassified

Order By: Relevance

“…(34). As we know, IBD increases the risk of severe diseases like colon cancer (35). However, pyroptosis palys a different role in cancers.…”

Section: Discussionmentioning

confidence: 99%

The pyroptosis related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma.

Jin

Zhuang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Dedifferentiated liposarcoma, a member of malignant mesenchymal tumors, has a high local recurrence rate and poor prognosis. Pyroptosis, a newly discovered programmed cell death, is tightly connected with the progression and outcome of tumor. However, the role of pyroptosis in Dedifferentiated liposarcoma remained unclear. Methods We obtained the RNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases to identify different pyroptosis-related genes (PRGs) expression patterns. An unsupervised method for clustering based on PRGs was performed. Clinical outcomes and immune microenvironment varied with the clusters according to the result of cluster analysis. The differentially expressed genes between the two clusters were used to develop a prognosis model by LASSO Cox regression method, followed by the performance of functional enrichment analysis and single-sample gene set enrichment analysis(ssGSEA). All of the above results were validated in Gene Expression Omnibus (GEO) dataset. Results Forty-one differentially expressed PRGs were found between tumor and normal tissues. DDL patients were classified into two clusters using consensus clustering analysis based on PRGs. Cluster 2 showed a better outcome, higher immune scores, stronger immune cells abundances, and elevated expression levels in numerous immune checkpoints compared with Cluster 1. Differentially expressed genes (DEGs) between clusters were identified. A total of 5 gene signature was built based on the DEGs and divided all DDL patients of the TCGA cohort into low-risk and high-risk groups. The low-risk group indicated greater inflammatory cell infiltration and better outcome. External validation verified significant differences of survival and immune landscape again between two risk groups of GEO cohort. Receiver operating characteristic (ROC) curves implied that risk model could exert its great value in predicting DDL patients’ prognoses. Conclusion Our findings revealed the clinical implication and key role in tumor immunity of pyroptosis-related genes in dedifferentiated liposarcoma. The risk model is a promising predictive tool, which could provide a fundamental basis for future studies and individualized immunotherapy.

show abstract

“…(34). As we know, IBD increases the risk of severe diseases like colon cancer (35). However, pyroptosis palys a different role in cancers.…”

Section: Discussionmentioning

confidence: 99%

The pyroptosis related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma.

Jin

Zhuang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…To determine how CI-associated disorders relate to one another, we used a network-based approach to quantify the similarity between their CI-enriched clusters. We hypothesized, for example, that Crohn’s disease and “malignant tumor of colon” would have similar CI-signatures, given that patients with inflammatory bowel disease are at increased risk for developing colorectal cancer (S. C. Shah and Itzkowitz 2022). However, Crohn’s disease CI-enriched clusters are members of signature groups 1 and 2, while the “malignant tumor of colon” CI-enriched cluster belongs to group 3 ( Fig.…”

Section: Discussionmentioning

confidence: 99%

A network-based approach for isolating the chronic inflammation gene signatures underlying complex diseases towards finding new treatment opportunities

Hickey

McKim

Mancuso

et al. 2022

Preprint

View full text Add to dashboard Cite

Complex diseases are associated with a wide range of cellular, physiological, and clinical phenotypes. To advance our understanding of disease mechanisms and our ability to treat these diseases, it is critical to delineate the molecular basis and therapeutic avenues of specific disease phenotypes, especially those that are associated with multiple diseases. Inflammatory processes constitute one such prominent phenotype, being involved in a wide range of health problems including ischemic heart disease, stroke, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, and autoimmune and neurodegenerative conditions. While hundreds of genes might play a role in the etiology of each of these diseases, isolating the genes involved in the specific phenotype (e.g. inflammation "component") could help us understand the genes and pathways underlying this phenotype across diseases and predict potential drugs to target the phenotype. Here, we present a computational approach that integrates gene interaction networks, disease-/trait-gene associations, and drug-target information to accomplish this goal. We apply this approach to isolate gene signatures of complex diseases that correspond to chronic inflammation and prioritize drugs to reveal new therapeutic opportunities.

show abstract

“…Colitis-associated cancer (CAC) is a complication of IBD and is also a common cause of cancer-related death ( 81 ). At present, the preventive effect of drug therapy on CAC is poor.…”

Section: Nutraceuticals For the Treatment Of Ibdmentioning

confidence: 99%

Nutraceuticals for the Treatment of IBD: Current Progress and Future Directions

et al. 2022

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic relapsing-remitting inflammatory disease of the gastrointestinal tract. Patients are usually diagnosed in adolescence and early adulthood and need lifelong treatment. In recent years, it has been found that diet plays an important role in the pathogenesis of IBD. Diet can change intestinal barrier function, affect the structure and function of intestinal flora, and promote immune disorder, thus promoting inflammation. Many patients believe that diet plays a role in the onset and treatment of the disease and changes their diet spontaneously. This review provides some insights into how nutraceuticals regulate intestinal immune homeostasis and improve intestinal barrier function. We reviewed the research results of dietary fiber, polyphenols, bioactive peptides, and other nutraceuticals in the prevention and treatment of IBD and sought better alternative or supplementary treatment methods for IBD patients.

show abstract

Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management

Cited by 372 publications

References 132 publications

The pyroptosis related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma.

The pyroptosis related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma.

A network-based approach for isolating the chronic inflammation gene signatures underlying complex diseases towards finding new treatment opportunities

Nutraceuticals for the Treatment of IBD: Current Progress and Future Directions

Contact Info

Product

Resources

About